BioMarker Strategies

Rockville, United States Founded: 2007 • Age: 19 yrs
Cancer diagnostics systems are developed for solid tumor predictive testing.

About BioMarker Strategies

BioMarker Strategies is a company based in Rockville (United States) founded in 2007.. BioMarker Strategies has raised $7.25 million across 14 funding rounds from investors including HHS, National Cancer Institute and NIH SBIR/STTR. BioMarker Strategies offers products and services including SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles. BioMarker Strategies operates in a competitive market with competitors including Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.

  • Headquarter Rockville, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $7.25 M (USD)

    in 14 rounds

  • Latest Funding Round
    $299.34 K (USD), Grant

    Sep 22, 2017

  • Investors
    HHS

    & 3 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of BioMarker Strategies

BioMarker Strategies offers a comprehensive portfolio of products and services, including SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Automates profiling of live tumor cells for predictive cancer treatment selection.

Generates predictive profiles from live cells for targeted therapy responses.

People of BioMarker Strategies
Headcount 10-50
Employee Profiles 1
Board Members and Advisors 2
Employee Profiles
People
Jerry Parrott
President & CEO

Unlock access to complete

Board Members and Advisors
people
Glenn Miller
Chair of the Scientific Advisory Board and a Director, BioMarker Strategies

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of BioMarker Strategies

BioMarker Strategies has successfully raised a total of $7.25M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $299.34 thousand completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 14
  • Last Round Grant — $299,340
  • First Round

    (23 Jun 2008)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2017 Amount Grant - BioMarker Strategies Valuation

investors

HHS
Aug, 2016 Amount Series A - BioMarker Strategies Valuation

investors

Jul, 2016 Amount Grant - BioMarker Strategies Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in BioMarker Strategies

BioMarker Strategies has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Cancer Institute and NIH SBIR/STTR. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Cancer research is conducted and supported by the institute.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by BioMarker Strategies

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - BioMarker Strategies

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biomarker Strategies Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of BioMarker Strategies

BioMarker Strategies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Health risks are identified through online genetic and diagnostic testing.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about BioMarker Strategies

When was BioMarker Strategies founded?

BioMarker Strategies was founded in 2007 and raised its 1st funding round 1 year after it was founded.

Where is BioMarker Strategies located?

BioMarker Strategies is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.

Is BioMarker Strategies a funded company?

BioMarker Strategies is a funded company, having raised a total of $7.25M across 14 funding rounds to date. The company's 1st funding round was a Grant of $2.3M, raised on Jun 23, 2008.

What does BioMarker Strategies do?

BioMarker Strategies was founded in 2007 in Rockville, United States, within the biotechnology sector focused on oncology. Cancer diagnostics systems, including SnapPath, are developed to enable predictive tests that guide targeted drug development and treatment selection for patients with solid tumor malignancies. PathMAP functional signaling profiles are generated using this system, serving as biomarker tests to predict individual responses to targeted therapies.

Who are the top competitors of BioMarker Strategies?

BioMarker Strategies's top competitors include Guardant Health, Juno Therapeutics and Foundation Medicine.

What products or services does BioMarker Strategies offer?

BioMarker Strategies offers SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles.

Who are BioMarker Strategies's investors?

BioMarker Strategies has 4 investors. Key investors include HHS, National Cancer Institute, NIH SBIR/STTR, and Abell Foundation.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available